Aptevo Therapeutics Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -22.22% | -223.53% | -101.27% | -102.96% | -101.34% |
| Gross Profit | 22.22% | 223.53% | 101.27% | 102.96% | 101.34% |
| SG&A Expenses | -6.52% | -13.79% | -13.14% | -12.29% | -12.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.36% | -14.26% | -14.81% | -18.47% | -17.36% |
| Operating Income | 6.36% | 14.26% | 14.81% | 18.47% | 17.36% |
| Income Before Tax | 4.84% | 13.21% | -29.38% | -36.30% | -32.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.84% | 13.21% | -29.38% | -36.30% | -32.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -80.03% | -82.05% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.72% | 12.27% | -38.58% | -46.87% | -42.91% |
| EBIT | 6.36% | 14.26% | 14.81% | 18.47% | 17.36% |
| EBITDA | 5.80% | 13.83% | 14.35% | 18.13% | 16.86% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |